B
uilding on the work of Mann et al 1 at Northwick Park Hospital in London, Coats et al 2 at the John Radcliffe Hospital in Oxford, and Perloff et al 3 at the San Francisco Medical Center, in 1988, Thomas Pickering coined the term white-coat hypertension, to describe patients whose blood pressure was elevated in the medical environment, but not during daytime ambulatory monitoring. 4, 5 Early pioneering studies [1] [2] [3] unambiguously established that ambulatory blood pressure is a better predictor of cardiovascular outcome than the in-office blood pressure and consequently surmised that white-coat hypertension must be associated with low cardiovascular risk. A seminal article by Pickering et al 4 included a statement that patients who showed an exaggerated response to the clinic environment might also exhibit a similar response to more regularly occurring types of stress, which could support the continued use of clinic blood pressure for making therapeutic decisions. However, observations by Pickering et al 4 did not support this preposition.
The first longitudinal study on the prognostic values of white-coat hypertension was reported in 1994. 6 On the basis of these early studies [1] [2] [3] [4] [5] [6] and confirmatory reports in patients 7 and populations, [8] [9] [10] [11] [12] the currently prevailing point of view is that white-coat hypertension carries little cardiovascular risk. 13 However, some researchers 14 suggested that white-coat hypertension is a heterogeneous condition. In making this statement, they did not refer to the loose criteria in the literature used to diagnose white-coat hypertension. They alluded to the fact that in some studies, white-coat hypertension, compared with true normotension, was associated with a higher prevalence of cardiovascular risk factors and target organ damage, 15 increased mortality, 15 more cardiovascular events, 16 and higher out-of-the-office blood pressure. 15, 16 In this article, we will demonstrate that labeling white-coat hypertension in this sense as a heterogeneous condition is erroneous because it is based on a combination of imprecise diagnostic criteria that overlook the true nature of white-coat hypertension and that white-coat hypertension is associated with low cardiovascular risk in the absence of other risk factors.
Determinants of White-Coat Hypertension
In 1994, in an analysis of the International Database of Ambulatory Blood Pressure Monitoring, we demonstrated that the probability of patients with office hypertension having a normal 24-hour blood pressure was higher in women than in men, increased with age, and was 2-to 4-fold greater if the office blood pressure had only been measured at a single visit or if fewer than 3 readings had been averaged. 17 In untreated participants with mild hypertension enrolled in the HARVEST (Hypertension and Ambulatory Recording Venetia Study) or the PIUMA (Progetto Ipertensione Umbria Monitoraggio Ambulatoriale) studies, white-coat hypertension was most frequent among women, nonsmokers, and individuals with low clinic blood pressure and smaller left ventricular mass. 18 In a more recent participant-level meta-analysis,
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we refined the assessment of the association of white (Figure 1 ). 11 The prevalence of white-coat hypertension exponentially increased from 2.2% to 19.5% from age 18 to 30 to ≥70 years, with little sex differences. 11 Along similar lines, in untreated participants enrolled in the SKIPOGH study (Swiss Kidney Project of Genes in Hypertension), older age was the sole determinant of whitecoat hypertension with education, family history of hypertension, and physical activity having no influence. 19 Other studies 20, 21 confirmed that the relation between office and home blood pressure, as other modality of out-of-the-office blood pressure measurement, changes according to age in a way similar as the relation between office and the ambulatory blood pressure does. 11 We recently assessed in 8237 untreated IDACO participants to what extent the time intervals, during which the ambulatory blood pressure is measured, affects cardiovascular risk. 12 We used the following hypertension thresholds ≥140/≥90, ≥130/≥80, ≥135/≥85, and ≥120/≥70 mm Hg for the office, 24-hour, daytime, and nighttime blood pressures, respectively (Table) . The prevalence of white-coat hypertension ranged from 6.3% to 12.5% depending on the time periods chosen. During 91 046 person-years, 729 cardiovascular events occurred. In multivariable-adjusted analyses, hazard ratios associated with white-coat hypertension progressively weakened (Figure 2) 12 Being normotensive over the whole 24-hour period was therefore associated with the lowest cardiovascular risk. 12 Within the daytime-based whitecoat hypertension, Considering daytime-defined white-coat hypertension, Verdecchia et al 23 suggested that lowering the threshold of daytime hypertension (eg, from 131/86 mm Hg in women and 136/87 mm Hg in men to 130/80 mm Hg in both sexes) would result in a lower event rate associated with white-coat hypertension.
Blood pressure self-measurement offers several of the well-recognized advantages of the more complex approach of ambulatory blood pressure monitoring. 24 The greater number of readings and the minimization of the white-coat effect contribute to a better diagnostic accuracy, compared with office blood pressure measurement. 24 If automated devices are used and if patients apply a standardized protocol for the timing of the measurements rather than initiating recordings based on symptoms, self-recorded blood pressure values are to a large extent free of observer bias. However, in 831 untreated Chinese outpatients, using daytime ambulatory instead of home blood pressure confirmed the cross-classification with office blood pressure only in 575 patients (69.2%), downgraded risk from masked hypertension to normotension (n=24) or from sustained to white-coat hypertension (n=9) in 33 patients (4.0%), but upgraded the risk from normotension to masked hypertension (n=179) or from white-coat to sustained hypertension (n=44) in 223 patients (26.8%). 25 These observations, 25 along with the IDACO data article referred to before, 12 indicate that the method of measuring out-of-the-office blood pressure substantially affects the prevalence of white-coat hypertension.
Although confined by definition to the normal blood pressure range, both ambulatory and home blood pressure are several mm Hg higher in white-coat hypertensive patients than in normotensive people.
14 However, this interpretation 14 disregards the effects on estimates of the prevalence of white-coat hypertension related to the frequency of office blood pressure measurements, 17 age, 11, 17 the modality used to measure the out-of-the-office blood pressure, 25 or the time intervals applied during ambulatory monitoring to diagnose white-coat hypertension.
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Influence of Treatment
In the literature, white-coat hypertension is varyingly defined based on the ambulatory blood pressure levels irrespective of treatment status 8 or in untreated persons only. 11, 12, 19 Initial analyses of the IDACO database did not account for treatment status. Using thresholds as proposed in current guidelines 22, 26 and office and daytime normotension as reference, the multivariable-adjusted hazard ratio for a cardiovascular event associated with white-coat hypertension was 1.22 (P=0.095). 8 Median follow-up was 9.5 years. If the Cox models were censored at 6, 9, and 12 years, the hazard ratios associated with white-coat hypertension were 1.08 (P=0.79), 1.20 (P=0.29), and 1.30 (P=0.043), respectively. 8 Compared with sustained hypertension, the hazard ratio for a cardiovascular end point associated with white-coat hypertension was consistently <0.73 (P≤0.014) lower, irrespective of the follow-up period considered. 8 Thus, follow-up duration is another key factor Figure 1 . Differences between office and ambulatory daytime blood pressures according to age categories. Data are mean±SE differences of office minus daytime blood pressure. DBP indicates diastolic blood pressure; and SBP, systolic blood pressure. Reprinted from Conen et al. 11 Copyright © 2014, American Heart Association, Inc.
to be considered in relating cardiovascular risk to white-coat hypertension. Until now, there is no proof that in studies with a sufficiently lengthy follow-up risk estimates are higher in white-coat hypertensive than normotensive people.
Subsequent IDACO analyses only included untreated people 9,10,12 and most recently 10 accounted for the huge effect of age on the prevalence of white-coat hypertension and the clustering of risk factors with both aging and white-coat hypertension. We scored cardiovascular risk by applying European Society Hypertension guidelines 22 to 653 untreated white-coat hypertensive patients matched with 653 normotensive controls by cohort and age (within 5 years), 10 an approach that is more bias-free than trying to adjust away the huge confounding effect of age. Over a median follow-up of 10.6 years, the incidence of cardiovascular end points was higher in 159 high-risk white-coat hypertensive patients compared with cohort-and age-matched high-risk normotensive people (adjusted hazard ratio, 2.06; P=0.023). The corresponding hazard ratio in 494 low-risk participants was not significant (1.06; P=0.80). After stratification for age (<60 versus ≥60 years), the association between cardiovascular risk and whitecoat hypertension was limited to senior high-risk white-coat hypertensive patients. 10 The hazard ratio associated with white-coat hypertension was higher (P=0.044) in older highrisk compared with older low-risk individuals (2.19 versus 0.88; P=0.027 versus 0.66). Below 60 years of age, the incidence of cardiovascular events in white-coat hypertensive participants was low without any tendency for increased risk compared with their cohort-and age-matched normotensive controls. Overall, there were 70 incident cardiovascular events in the white-coat hypertensive patients versus 48 in the cohort-and age-matched normotensive participants, meaning that there was an excess of only 22 new cardiovascular events, affecting only 3.4% of the 653 white-coat hypertensive patients and leaving 96.6% of the white-coat population at no greater risk than cohort-and age-matched normotensive controls. 10 Pierdomenico and Cuccurullo 13 did a meta-analysis of summary statistics to assess the prognostic impact of whitecoat hypertension in initially untreated people free of cardiovascular complications, which included the availability of covariables to adjust the hazard ratios for confounders. They identified 6 studies, 6, 7, [27] [28] [29] [30] including untreated participants with white-coat hypertension. Four studies 7,28-30 used <135/<85 mm Hg as daytime ambulatory threshold, one 27 used <130/<80 mm Hg as 24-hour threshold, and one 6 applied sexspecific thresholds for the daytime blood pressure (<131/86 mm Hg in women and <136/87 mm Hg in men). In this metaanalysis, 1 study by Hansen et al 29 provided updated data for untreated participants. Compared with normotension, the pooled hazard ratio of white-coat hypertension for the incidence of cardiovascular events was 0.96 (95% confidence intervals [CIs], 0.65-1.42; P=0.85) without any heterogeneity 
Blood pressure thresholds are given in mm Hg. Automated office blood pressure is the mean of multiple blood pressure readings recorded with a fully automated device with the patient resting silently, alone, in a quiet room at the doctor's office or clinic. Consensus classification proposed by the 2013 European guidelines.
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Figure 2. Risk of a cardiovascular outcome associated with whitecoat hypertension as recorded during varying intervals during the day. White-coat hypertension was office hypertension in the presence of a normal ambulatory blood pressure. When systolic or diastolic blood pressure was in different categories (normotensive vs hypertensive), participants were classified as hypertensive. Hazard ratios were multivariable adjusted. Horizontal bars denote the 95% confidence interval. Reprinted from Asayama et al. 12 Copyright © 2014, American Heart Association, Inc.
between studies (P>0.65; Figure 3) , and follow-up duration did not affect this conclusion. This exemplary meta-analysis 13 accurately dealt with the problem of confounding by antihypertensive drug treatment.
Total and Cardiovascular Risk
In each participant of the population in the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni), 31 3 office blood pressure readings at a single visit, a 24-hour ambulatory blood pressure recording, and 2 home blood pressure measurements, one in the morning and one in the evening, were obtained. The proportion of participants on antihypertensive drug treatment was 4.3% in 825 normotensive people and 31.0% in 227 patients with partial white-coat hypertension, as diagnosed by either ambulatory or home blood pressure monitoring, and 22.0% in 164 true white-coat hypertensive patients, who had a normal out-of-the-office blood pressure both on ambulatory and home blood pressure monitoring. It is not surprising that by including treated participants, the results were contradictory. With normotension as the reference group, the hazard ratios for total mortality were 1.35 (CI, 0.81-2.23; P=0.25) and 1.58 (CI, 1.05-2.38; P=0.027) in true (22 deaths) and partial (55 deaths) white-coat hypertensive participants; for cardiovascular mortality, the corresponding estimates were 0.67 (CI, 0.14-3.18; P=0.61; 2 deaths) and 2.76 (CI, 1.16-6.59; P=0.022; 19 deaths). 31 The partial white-coat hypertensive group probably included a proportion of patients with sustained hypertension. The models, including 4 blood pressure groups, were adjusted for sex, age, body mass index, blood glucose, serum total cholesterol, smoking, previous cardiovascular disease, and antihypertensive drug treatment. There were few events, in particular, from cardiovascular mortality, relative to the number of independent variables possibly leading to uncertain results. Moreover, the introduction of stroke units and invasive coronary procedures in routine clinical care has substantially decreased the case fatality rates of most cardiovascular complications of hypertension. Not accounting for nonfatal events, therefore, limits the generalizability of the PAMELA results. 31 A Taiwanese study included 1257 never-treated volunteers from a community-based survey. 32 Of those, 250 were normotensive people with an office blood pressure of <120 mm Hg systolic and 80 mm Hg diastolic; 318 were participants with prehypertension, who had an office blood pressure between 120/80 and 140/90 mm Hg and normal daytime ambulatory blood pressure; and 153 were white-coat hypertensive patients. During a median follow-up period of 15 years, 272 died, but only 73 (26.8%) from cardiovascular disease. 32 The incidence of all-cause and cardiovascular mortality expressed per 1000 person-years of follow-up was 9.7 and 0.6 in normotensive people, 11.0 and 1.4 in prehypertensive participants, and 24.6 and 6.5 in white-coat hypertensive patients. 32 Multivariable models were adjusted for sex, age, body mass index, smoking, fasting plasma glucose, and the total:high-density lipoprotein serum cholesterol ratio. Compared with normotension, the hazard ratios associated with white-coat hypertension were 1.30 (CI, 0.81-2.09) and 5.59 (CI, 1.22-25.6) for total and cardiovascular mortality, respectively. 32 As in the PAMELA study, 31 the Taiwanese study 32 was underpowered to assess cardiovascular mortality, resulting in extremely wide CIs and did also not account for the incidence of nonfatal cardiovascular events.
That cardiovascular mortality in the Taiwanese study 32 represented only one fourth of all-cause mortality highlights the relevance of the latter issue. Moreover, prehypertensive participants were excluded from the control group, leading to an underestimation of the risk associated with normotension. 32 White-coat hypertensive participants were significantly older and had greater body mass index, blood pressure values, intima-media thickness, carotid-femoral pulse wave velocity, central augmentation index, amplitude of the backward pressure wave, and a lower estimated glomerular filtration compared with prehypertensive individuals. 32 This illustrates the superiority of the IDACO approach, 10 in which normotensive and white-coat hypertensive participants were matched by age with normotensive controls and in which analyses were stratified by age and cardiovascular risk. 10 The results of another study, the DHS (Dallas Heart Study), which attempts to determine hypertensive target organ damage and adverse cardiovascular outcomes associated with white-coat hypertension, is also flawed. 16 This study includes a probability-based population cohort (n=3027 at baseline) with oversampling of blacks (50.0%). The sample-weighted prevalence rate of white-coat hypertension at baseline (3.3%) was ≈4-fold lower than in other population studies. 12 The obvious explanation is that the same observers measured blood pressure at the homes of the participants and subsequently at the clinic and that of 5 blood pressure readings at each occasion, only the third to fifth were averaged for analysis. In 2073 participants followed up for a median of 9.4 years, 52 composite cardiovascular events occurred in 1627 normotensive participants but only 10 in 109 white-coat hypertensive patients. The cardiovascular end point included cardiovascular death, coronary heart disease, stroke, heart failure, but also the weaker outcome of atrial fibrillation. 16 The contribution of each of these outcomes to the composite end point was not reported. 16 Outcome analyses did not include patients with a previous history of cardiovascular disease and were adjusted for ethnicity, sex, age, body mass index, diabetes mellitus, serum cholesterol, smoking, self-reported history of hypertension, and antihypertensive treatment. With these adjustments applied, the hazard ratio, as the authors stated, 16 trended to significance, amounting to 1.98 (CI, 0.99-3.95; P=0.051).
Briasoulis et al 33 published a meta-analysis of summary statistics extracted from 14 studies including 13 538 normotensive and 4806 white-coat hypertensive patients. The incidence of cardiovascular events was 6% in white-coat hypertensive patients and 4% in normotensive people. The odds ratio of a cardiovascular event associated with whitecoat hypertension compared with normotension was 1.73 (CI, 1.27-2.36; P=0.006). However, this study 33 is uninterpretable because the authors pooled studies based on daytime and home blood pressure monitoring to define white-coat hypertension, and the analyses were completely unadjusted and notably did not account for age or treatment status. By way of comparison, the Ohasama study group originally reported that the multivariable-adjusted cardiovascular risk among participants with white-coat hypertension, including both treated and untreated residents, was much lower, that is, 1.28 (CI, 0.76-2.14; P=0.40). (8 656) , and 12 (21 336) cohorts for analysis of cardiovascular risk, respectively, associated with white-coat hypertension in patients without or under antihypertensive treatment at baseline or including both untreated and treated participants. In untreated cohorts, compared with normotension, white-coat hypertension was associated with 38% and 20% risk increments of cardiovascular disease and total mortality. However, in treated patients, neither the risk of cardiovascular disease nor total mortality was increased in white-coat hypertension. As highlighted before, total mortality is an administrative end point, easily obtained from population registries and since the introduction of invasive therapies in cardiovascular disease carrying little information. In subgroup analyses, white-coat hypertension was suboptimally defined using varying approaches to measure blood pressure or to define a composite cardiovascular end point. For instance, Huang et al 34 included a recent IDACO analysis, 12 but selected the daytime only or 24-hour only ambulatory blood pressure-based statistics, thereby overestimating the risk of white-coat hypertension compared with ambulatory normotension over the whole day. They also referenced our home blood pressure-based individual participant database, including 5007 untreated and 1451 treated participants enrolled in 5 cohorts, 35 who monitored their home blood pressure for a single day up to >3 weeks (7 days in 84% of the participants). If participants were analyzed with ≥7 days of home blood pressure monitoring, as recommended by present-day guidelines, 22, 36 home blood pressure-based white-coat hypertension was no longer associated with an increased cardiovascular risk.
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Conclusions
White-coat hypertension is commonly defined as a raised inoffice blood pressure in the presence of a normal out-of-theoffice blood pressure. In the light of the evidence reviewed in this debate, we propose that this definition be refined. One possibility, as suggested by Myers and Stergiou, 38 is to change the nomenclature from white-coat hypertension to white-coat phenomenon to remove the stigma of hypertension. Although the white-coat phenomenon rightly denotes the white-coat effect, it is, in our opinion, a misnomer to refer to whitecoat hypertension because the this condition may be present both in untreated and treated individuals. Alternatively, an elevated office pressure in the presence of a normal out-ofthe-office blood pressure in untreated people might be called masked normotension, a term proposed previously by others 39 although not accounting for treatment status. Masked normotension, which is not associated with increased cardiovascular risk, and which should not be treated by blood pressure-lowering drugs, does requires management of cardiovascular risk factors and further follow-up. The widespread assumption that masked normotension predisposes to the development of sustained hypertension, 40, 41 to our knowledge, has never been tested by long-term follow-up of truly normotensive and masked normotensive people, matched for age at baseline. An elevated office pressure in the presence of a normal out-of-theoffice blood pressure in treated patients reflects hypertension controlled under out-of-the-office conditions, but uncontrolled in a medical environment. For this group, the term white-coat hypertension might still be appropriate on condition that treatment is given correctly, as recommended by current guidelines. Unfortunately, this is not always the case.
We agree with 1 point raised by Mancia and Grassi, 14 who state that white-coat hypertension is a heterogeneous condition. For this very reason, studies should account for age, 11, 17 for the presence of cardiovascular risk factors, for the number of visits and the number of blood pressure readings used to define the office blood pressure, 17 the modality of out-of-theoffice measurement, 25 the number and definition of end points available for analysis, 31, 32 and the proportionality between the number of end points and confounders adjusted for. 31, 32 Furthermore, definition of white-coat hypertension differs across the studies, which affect the risk of white-coat hypertension. 12, 23 If ambulatory blood pressure measurement is used to define white-coat hypertension, the period of the day during which blood pressure was within the normal range must be stated 12 ; if home blood pressure monitoring is applied, current guidelines recommend at least 3 to 4 22 but preferably 5 to 7 consecutive days of measurement per week. 22, 36 These quality standards might inform the future research agenda and the criteria to be met for new publications on the subject and for truly evidence-based guidelines for the diagnosis and management of white-coat hypertension.
Response to Cardiovascular Risk Associated With White-Coat Hypertension:
Con Side of the Argument
Giuseppe Mancia, Michele Bombelli, Cesare Cuspidi, Rita Facchetti, Guido Grassi
Any controversy on the clinical value of white-coat hypertension (WCH) cannot deny a simple fact, namely, that when physicians (who are not asked to adjust their observations for covariates!) see a patient with an elevation of office blood pressure and an out-of-office blood pressure within the accepted normal limits, they must suspect a clinically abnormal condition and proceed to clinical investigations that are not required in patients in whom the above pressures are both normal. This will disclose considerably more often than in normotensive individuals an array of associated metabolic risk factors but also organ alterations that are normally caused by a blood pressure elevation such as left ventricular hypertrophy, suggesting that the abnormal in-office and out-of-office blood pressure pattern is involved. We think that the clinical abnormality of WCH has received confirmation from (1) meta-analyses of longitudinal outcome studies that have documented its association with an increased cardiovascular risk and (2) evidence that WCH individuals' progression to high cardiovascular risk conditions (established hypertension and diabetes mellitus) is substantially more frequently than in normotensive people. This is the case also for the development of organ damage in patients who do not have it originally, that is, a condition regarded by our opponents as of no risk. We think it is time to move from this established background to research on issues of mechanistic and clinical relevance that are not clear. One of them may be the identification of WCH subgroups at higher or lower risk, perhaps acknowledging, however, that in several instances (eg, treated WCH), the nature of the available information makes unequivocal evidence difficult to be obtained. Another is to determine whether and to what extent in WCH drug treatment of the abnormal risk profile can reduce the cardiovascular risk and slow down progression to high-risk conditions that will inevitably affect their life time prognosis.
